Intelligent Bio Solutions ( (INBS) ) has issued an announcement.
Intelligent Bio Solutions Inc. has announced significant progress in its clinical study plan, a crucial step toward FDA 510(k) submission for its non-invasive drug screening technology. Partnering with CenExel, the company is conducting a method comparison study, having enrolled one-third of the required subjects to compare its fingerprint sweat opiate screening with laboratory LC-MS/MS methods. With in-clinic portions of pharmacokinetic studies on opiates in fingerprint sweat concluding and analysis underway, INBS aims to complete the study by September end and prepare for FDA submission in late 2024. The technology offers quick, hygienic, and accurate drug screening, promising to transform portable testing in various industries and healthcare settings.
For an in-depth examination of INBS stock, go to TipRanks’ Stock Analysis page.
